USNA vs PLBY

For growth investors, USANA Health Sciences, Inc.

(USNA) is the stronger pick with 8. 3% revenue growth year-over-year, versus 4. 1% for Playboy, Inc. (PLBY). USANA Health Sciences, Inc. (USNA) offers the better valuation at 33. 6x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Playboy, Inc. (PLBY) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, USANA Health Sciences, Inc.

is actually cheaper at 11. 2x.

Over the past 5 years, USANA Health Sciences, Inc.

(USNA) delivered a total return of -80. 0%, compared to -96. 6% for Playboy, Inc. (PLBY). Over 10 years, the gap is even starker: USNA returned -68. 7% versus PLBY's -83. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), USANA Health Sciences, Inc.

(USNA) is the lower-risk stock at 1. 34β versus Playboy, Inc. 's 1. 96β — meaning PLBY is approximately 46% more volatile than USNA relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 130% for Playboy, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), USANA Health Sciences, Inc.

(USNA) is pulling ahead at 8. 3% versus 4. 1% for Playboy, Inc. (PLBY). On earnings-per-share growth, the picture is similar: Playboy, Inc. grew EPS 87. 5% year-over-year, compared to -73. 5% for USANA Health Sciences, Inc.. Over a 3-year CAGR, USNA leads at -2. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

USANA Health Sciences, Inc.

(USNA) is the more profitable company, earning 1. 2% net margin versus -10. 5% for Playboy, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USNA leads at 5. 5% versus -2. 7% for PLBY. At the gross margin level — before operating expenses — USNA leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, USANA Health Sciences, Inc.

(USNA) trades at 11. 2x forward P/E versus 22. 8x for Playboy, Inc. — 11. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PLBY: 656. 3% to $12. 63.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, USANA Health Sciences, Inc.

(USNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Playboy, Inc. (PLBY) carries a higher beta of 1. 96 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (USNA: -68. 7%, PLBY: -83. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (USNA (Consumer Defensive) and PLBY (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.